---
layout: default
title: Ganirelix
parent: Model Prediction Only (L5)
nav_order: 329
evidence_level: L5
indication_count: 10
---

# Ganirelix
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ganirelix: From Controlled Ovarian Stimulation to Hypertrichosis

## One-Sentence Summary

Ganirelix is a GnRH receptor antagonist used to prevent premature ovulation in women undergoing ovarian stimulation during fertility treatment.
The TxGNN model predicts it may be effective for **hypertrichosis**, but there are currently **0 clinical trials** and **0 publications** supporting this direction.
The prediction is model-based only, and no plausible mechanistic pathway has been identified.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Prevention of premature ovulation during ovarian stimulation in fertility treatment (the ARTG entry lists no indication text; this is based on the pharmacology data compiled for this report) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Australia Market Status | Marketed |
| Number of ARTG Entries | 1 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Pharmacology data identify ganirelix as an antagonist of the GnRH receptor (GNRHR). By blocking this receptor, it suppresses LH and FSH release and, downstream, gonadal sex steroids.

This mechanism does not clearly connect to hypertrichosis. Hypertrichosis is not primarily driven by gonadotropins, unlike hirsutism, which is androgen-dependent. The high TxGNN score appears to be a graph-based prediction with no identifiable biological pathway, and it should be treated as a hypothesis-generating signal only.

The other top-ranked predictions show the same pattern. Most are developmental or structural conditions with no plausible link to GnRH antagonism (for example, Ambras syndrome, Dandy-Walker malformation syndromes and isolated hair shaft abnormalities). A few sit within the reproductive endocrine domain and are biologically more coherent, although none has clinical support here:

- **Central precocious puberty:** GnRH receptor blockade is mechanistically sound, but GnRH agonists are the established standard of care. Ganirelix's short half-life and daily injection limit its practicality.
- **Familial male-limited precocious puberty:** The defect (activating LHCGR mutations) lies downstream of GnRH, so efficacy would be expected to be limited.
- **Aromatase excess syndrome:** Excess oestrogen arises mainly from peripheral aromatisation, which GnRH antagonism would not address.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Australia Market Information

| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| ARTG 9583J | GANIRELIX SUN | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Not stated in the data compiled for this report |

## Safety Considerations

- **Drug Interactions:** Seven interaction records were identified. Six are rated Moderate (DDInter) and involve other agents acting on the reproductive hormone axis:
  - Gonadorelin
  - Chorionic gonadotropin (human)
  - Menotropins
  - Triptorelin
  - Follitropin
  - Urofollitropin

  The seventh is a pharmacology record confirming ganirelix's target, the GnRH receptor, and is not an interaction.

Warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction for hypertrichosis rests on a graph-based score alone, with no clinical trials, no literature and no plausible mechanism. Of the other top-ranked candidates, only central precocious puberty, familial male-limited precocious puberty and aromatase excess syndrome have any biological coherence. Each of these is better served by existing therapies and has no supporting clinical data.

**To proceed, the following is needed:**
- Product Information (PI) warnings and contraindications, which are currently a blocking gap for safety screening
- Mechanism of action data (for example, from DrugBank) to support a mechanistic-link analysis
- Systematic literature and trial searches for hypertrichosis, and for central precocious puberty if that is pursued as a research question
- Confirmation of the approved indication text for ARTG 9583J
- Route and formulation compatibility assessment for any new indication, including paediatric use
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

